{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:57:58Z","timestamp":1791925078394,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiologie"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00117-025-01477-3","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T15:12:27Z","timestamp":1749654747000},"page":"518-524","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Strahlentherapie von Non-Hodgkin-Lymphomen\u00a0\u2013 Diskussion moderner Behandlungskonzepte und Innovationen","Radiotherapy of non-Hodgkin lymphoma\u2014discussion of modern treatment concepts and innovations"],"prefix":"10.1007","volume":"65","author":[{"given":"Michael","family":"Oertel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Theodor","family":"Eich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,11]]},"reference":[{"key":"1477_CR1","doi-asserted-by":"publisher","first-page":"100832","DOI":"10.1016\/j.ctro.2024.100832","volume":"48","author":"HS Ababneh","year":"2024","unstructured":"Ababneh\u00a0HS, Johnson\u00a0CP, Pursley\u00a0J, Patel\u00a0CG (2024) Adaptive bridging radiation therapy for relapsed\/refractory B\u2011cell lymphoma patient undergoing CAR T\u2011cell therapy: Case report. Clin Transl Radiat Oncol 48:100832. https:\/\/doi.org\/10.1016\/j.ctro.2024.100832","journal-title":"Clin Transl Radiat Oncol"},{"key":"1477_CR2","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio\u00a0R, Amador\u00a0C, Anagnostopoulos\u00a0I et\u00a0al (2022) The 5th\u00a0edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 36:1720\u20131748. https:\/\/doi.org\/10.1038\/s41375-022-01620-2","journal-title":"Leukemia"},{"key":"1477_CR3","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","volume":"19","author":"L Amini","year":"2022","unstructured":"Amini\u00a0L, Silbert\u00a0SK, Maude\u00a0SL et\u00a0al (2022) Preparing for CAR T\u00a0cell therapy: patient selection, bridging therapies and lymphodepletion. Nat Rev Clin Oncol 19:342\u2013355. https:\/\/doi.org\/10.1038\/s41571-022-00607-3","journal-title":"Nat Rev Clin Oncol"},{"key":"1477_CR4","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1182\/blood.2022016945","volume":"140","author":"R Di Blasi","year":"2022","unstructured":"Di Blasi\u00a0R, Le Gouill\u00a0S, Bachy\u00a0E et\u00a0al (2022) Outcomes of patients with aggressive B\u2011cell lymphoma after failure of anti-CD19 CAR T\u2011cell therapy: a\u00a0DESCAR\u2011T analysis. Blood 140:2584\u20132593. https:\/\/doi.org\/10.1182\/blood.2022016945","journal-title":"Blood"},{"key":"1477_CR5","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3390\/lymphatics1030017","volume":"1","author":"HT Eich","year":"2023","unstructured":"Eich\u00a0HT, Pepper\u00a0NB, Oertel\u00a0M (2023) Evolution of Radiation Fields from Involved Field to Involved Site\u2014A Summary of the Current Guidelines by the International Lymphoma Radiation Oncology Group. Lymphatics 1:262\u2013272. https:\/\/doi.org\/10.3390\/lymphatics1030017","journal-title":"Lymphatics"},{"key":"1477_CR6","doi-asserted-by":"publisher","first-page":"109580","DOI":"10.1016\/j.radonc.2023.109580","volume":"183","author":"J Fan","year":"2023","unstructured":"Fan\u00a0J, Adams\u00a0A, Sieg\u00a0N et\u00a0al (2023) Potential synergy between radiotherapy and CAR T\u2011cells\u2014a\u00a0multicentric analysis of the role of radiotherapy in the combination of CAR T\u00a0cell therapy. Radiother Oncol 183:109580. https:\/\/doi.org\/10.1016\/j.radonc.2023.109580","journal-title":"Radiother Oncol"},{"key":"1477_CR7","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.ijrobp.2021.06.038","volume":"111","author":"NB Figura","year":"2021","unstructured":"Figura\u00a0NB, Robinson\u00a0TJ, Sim\u00a0AJ et\u00a0al (2021) Patterns and Predictors of Failure in Recurrent or Refractory Large B\u2011Cell Lymphomas After Chimeric Antigen Receptor T\u2011Cell Therapy. Int J Radiat Oncol Biol Phys 111:1145\u20131154. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.06.038","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1477_CR8","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1182\/blood.2020005846","volume":"137","author":"CL Freeman","year":"2021","unstructured":"Freeman\u00a0CL, Savage\u00a0KJ, Villa\u00a0DR et\u00a0al (2021) Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B\u2011cell lymphoma treated with R\u2011CHOP. Blood 137:929\u2013938. https:\/\/doi.org\/10.1182\/blood.2020005846","journal-title":"Blood"},{"key":"1477_CR9","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.1200\/JCO.2012.48.0467","volume":"31","author":"G Held","year":"2013","unstructured":"Held\u00a0G, Zeynalova\u00a0S, Murawski\u00a0N et\u00a0al (2013) Impact of rituximab and radiotherapy on outcome of patients with aggressive B\u2011cell lymphoma and skeletal involvement. J\u00a0Clin Oncol 31:4115\u20134122. https:\/\/doi.org\/10.1200\/JCO.2012.48.0467","journal-title":"J Clin Oncol"},{"key":"1477_CR10","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S1470-2045(20)30686-0","volume":"22","author":"P Hoskin","year":"2021","unstructured":"Hoskin\u00a0P, Popova\u00a0B, Schofield\u00a0O et\u00a0al (2021) 4\u202fGy versus 24\u202fGy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a\u00a0multicentre, randomised, phase\u00a03, non-inferiority trial. Lancet Oncol 22:332\u2013340. https:\/\/doi.org\/10.1016\/S1470-2045(20)30686-0","journal-title":"Lancet Oncol"},{"key":"1477_CR11","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S1470-2045(14)70036-1","volume":"15","author":"PJ Hoskin","year":"2014","unstructured":"Hoskin\u00a0PJ, Kirkwood\u00a0AA, Popova\u00a0B et\u00a0al (2014) 4\u202fGy versus 24\u202fGy radiotherapy for patients with indolent lymphoma (FORT): a\u00a0randomised phase\u00a03 non-inferiority trial. Lancet Oncol 15:457\u2013463. https:\/\/doi.org\/10.1016\/S1470-2045(14)70036-1","journal-title":"Lancet Oncol"},{"key":"1477_CR12","doi-asserted-by":"publisher","first-page":"259.e1","DOI":"10.1016\/j.jtct.2022.12.021","volume":"29","author":"H Hubbeling","year":"2023","unstructured":"Hubbeling\u00a0H, Silverman\u00a0EA, Michaud\u00a0L et\u00a0al (2023) Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed\/Refractory Aggressive B\u00a0Cell Lymphomas Prior to Chimeric Antigen Receptor T\u00a0Cell Therapy. Transplant Cell Ther 29:259.e1\u2013259.e10. https:\/\/doi.org\/10.1016\/j.jtct.2022.12.021","journal-title":"Transplant Cell Ther"},{"key":"1477_CR13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ijrobp.2014.01.006","volume":"89","author":"T Illidge","year":"2014","unstructured":"Illidge\u00a0T, Specht\u00a0L, Yahalom\u00a0J et\u00a0al (2014) Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 89:49\u201358. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.01.006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1477_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/bjh.16541","volume":"190","author":"BS Imber","year":"2020","unstructured":"Imber\u00a0BS, Sadelain\u00a0M, DeSelm\u00a0C et\u00a0al (2020) Early experience using salvage radiotherapy for relapsed\/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T\u00a0cell therapy. Br J Haematol 190:45\u201351. https:\/\/doi.org\/10.1111\/bjh.16541","journal-title":"Br J Haematol"},{"key":"1477_CR15","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1186\/s13063-019-3614-y","volume":"20","author":"L K\u00f6nig","year":"2019","unstructured":"K\u00f6nig\u00a0L, Dreyling\u00a0M, D\u00fcrig\u00a0J et\u00a0al (2019) Therapy of nodal Follicular Lymphoma (WHO grade\u00a01\/2) in clinical stage\u00a0I\/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro)\u2014GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a\u00a0study protocol for a\u00a0single-arm, non-randomized, open, national, multi-center phase\u00a0II trial. Trials 20:544. https:\/\/doi.org\/10.1186\/s13063-019-3614-y","journal-title":"Trials"},{"key":"1477_CR16","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1007\/s00066-018-1277-3","volume":"194","author":"L K\u00f6nig","year":"2018","unstructured":"K\u00f6nig\u00a0L, H\u00f6rner-Rieber\u00a0J, Bernhardt\u00a0D et\u00a0al (2018) Response rates and recurrence patterns after low-dose radiotherapy with 4\u202fGy in patients with low-grade lymphomas. Strahlenther Onkol 194:454\u2013461. https:\/\/doi.org\/10.1007\/s00066-018-1277-3","journal-title":"Strahlenther Onkol"},{"key":"1477_CR17","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF (2022) Diagnostik, Therapie und Nachsorge f\u00fcr erwachsene Patient*innen mit einem diffusen gro\u00dfzelligen B\u2011Zell-Lymphom und verwandten Entit\u00e4ten, Langversion 1.0, 2022, AWMF-Registernummer: 018\/038OL. https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/dlbcl\/;. Zugegriffen: 31. Juli 2023"},{"key":"1477_CR18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","volume":"100","author":"L Lowry","year":"2011","unstructured":"Lowry\u00a0L, Smith\u00a0P, Qian\u00a0W et\u00a0al (2011) Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a\u00a0randomised phase\u00a0III trial. Radiother Oncol 100:86\u201392. https:\/\/doi.org\/10.1016\/j.radonc.2011.05.013","journal-title":"Radiother Oncol"},{"key":"1477_CR19","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1200\/JCO.2018.77.9892","volume":"36","author":"M MacManus","year":"2018","unstructured":"MacManus\u00a0M, Fisher\u00a0R, Roos\u00a0D et\u00a0al (2018) Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03. J\u00a0Clin Oncol 36:2918\u20132925. https:\/\/doi.org\/10.1200\/JCO.2018.77.9892","journal-title":"J Clin Oncol"},{"key":"1477_CR20","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ijrobp.2019.02.001","volume":"104","author":"NG Mikhaeel","year":"2019","unstructured":"Mikhaeel\u00a0NG, Milgrom\u00a0SA, Terezakis\u00a0S et\u00a0al (2019) The Optimal Use of Imaging in Radiation Therapy for Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys 104:501\u2013512. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.02.001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1477_CR21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00066-022-02035-9","volume":"199","author":"M Oertel","year":"2023","unstructured":"Oertel\u00a0M, Berdel\u00a0C, Held\u00a0G et\u00a0al (2023) The new German evidence-based guideline on diffuse large B\u2011cell lymphoma-key aspects for radiation oncologists. Strahlenther Onkol 199:115\u2013120. https:\/\/doi.org\/10.1007\/s00066-022-02035-9","journal-title":"Strahlenther Onkol"},{"key":"1477_CR22","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s00066-019-01541-7","volume":"196","author":"M Oertel","year":"2020","unstructured":"Oertel\u00a0M, Elsayad\u00a0K, Weishaupt\u00a0C et\u00a0al (2020) De-escalated radiotherapy for indolent primary cutaneous B\u2011cell lymphoma. Strahlenther Onkol 196:126\u2013131. https:\/\/doi.org\/10.1007\/s00066-019-01541-7","journal-title":"Strahlenther Onkol"},{"key":"1477_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02231-9","author":"M Oertel","year":"2024","unstructured":"Oertel\u00a0M, Ziepert\u00a0M, Frontzek\u00a0F et\u00a0al (2024) Radiotherapy in younger patients with advanced aggressive B\u2011cell lymphoma-long-term results from the phase\u00a03\u202fR-MegaCHOEP trial. Leukemia. https:\/\/doi.org\/10.1038\/s41375-024-02231-9","journal-title":"Leukemia"},{"issue":"22","key":"1477_CR24","doi-asserted-by":"publisher","first-page":"00086","DOI":"10.1053\/j.semnuclmed.2022.09.001","volume":"S0001-2998","author":"NB Pepper","year":"2022","unstructured":"Pepper\u00a0NB, Oertel\u00a0M, Rehn\u00a0S et\u00a0al (2022) Modern PET-guided radiotherapy planning and treatment for malignant lymphoma. Semin Nucl Med S0001-2998(22):86\u201381. https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.09.001","journal-title":"Semin Nucl Med"},{"key":"1477_CR25","doi-asserted-by":"publisher","first-page":"7506","DOI":"10.1200\/JCO.2017.35.15_suppl.7506","volume":"35","author":"M Pfreundschuh","year":"2017","unstructured":"Pfreundschuh\u00a0M, Christofyllakis\u00a0K, Altmann\u00a0B et\u00a0al (2017) Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a\u00a0planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL\u300960\u00a0study of the DSHNHL. JCO 35:7506\u20137506. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.7506","journal-title":"JCO"},{"key":"1477_CR26","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1182\/bloodadvances.2020001837","volume":"4","author":"CC Pinnix","year":"2020","unstructured":"Pinnix\u00a0CC, Gunther\u00a0JR, Dabaja\u00a0BS et\u00a0al (2020) Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B\u2011cell lymphoma. Blood Adv 4:2871\u20132883. https:\/\/doi.org\/10.1182\/bloodadvances.2020001837","journal-title":"Blood Adv"},{"key":"1477_CR27","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.21873\/anticanres.14400","volume":"40","author":"S Rehn","year":"2020","unstructured":"Rehn\u00a0S, Elsayad\u00a0K, Oertel\u00a0M et\u00a0al (2020) Radiotherapy Dose and Volume De-escalation in Ocular Adnexal Lymphoma. Anticancer Res 40:4041\u20134046. https:\/\/doi.org\/10.21873\/anticanres.14400","journal-title":"Anticancer Res"},{"key":"1477_CR28","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1182\/bloodadvances.2022009019","volume":"7","author":"C Roddie","year":"2023","unstructured":"Roddie\u00a0C, Neill\u00a0L, Osborne\u00a0W et\u00a0al (2023) Effective bridging therapy can improve CD19 CAR\u2011T outcomes while maintaining safety in patients with large B\u2011cell lymphoma. Blood Adv 7:2872\u20132883. https:\/\/doi.org\/10.1182\/bloodadvances.2022009019","journal-title":"Blood Adv"},{"key":"1477_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijrobp.2015.01.009","volume":"92","author":"J Yahalom","year":"2015","unstructured":"Yahalom\u00a0J, Illidge\u00a0T, Specht\u00a0L et\u00a0al (2015) Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 92:11\u201331. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.01.009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1477_CR30","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF S3-Leitlinie Diagnostik, Therapie und Nachsorge f\u00fcr Patienten mit einem follikul\u00e4ren Lymphom, Langversion 1.0, 2020, AWMF-Registernummer: 018\/033OL. https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/follikulaeres-lymphom\/. Zugegriffen: 29. Sept. 2024"}],"container-title":["Die Radiologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-025-01477-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00117-025-01477-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-025-01477-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T12:29:37Z","timestamp":1750940977000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00117-025-01477-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1477"],"URL":"https:\/\/doi.org\/10.1007\/s00117-025-01477-3","relation":{},"ISSN":["2731-7048","2731-7056"],"issn-type":[{"value":"2731-7048","type":"print"},{"value":"2731-7056","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,11]]},"assertion":[{"value":"11 June 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Oertel und H.T.\u00a0Eich geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}